Volatile anaesthetics are often used during cardiopulmonary bypass (CPB). To understand the kinetics of inhaled anaesthetics during CPB, anaesthetists should understand changes in blood solubility caused by¯uid use. We set out to predict the solubility of three volatile anaesthetics, des¯urane, iso¯urane and halothane, during CPB by determining: (i) their solubility in fresh whole blood and eight CPB priming¯uids at 37°C; (ii) the effect of temperature on the solubility of these anaesthetics in lactated Ringer's, gelofusin, banked blood and plasma; (iii) their solubility in different mixtures of these four priming¯uids at different temperatures; and (iv) their estimated and actual solubility in blood during hypothermic CPB. We calculated solubility using a concept of volume fraction partition coef®cient and compared estimated and measured solubilities. For the three anaesthetics tested, solubilities are in the order: fresh whole blood » plasma > banked blood > normal saline » lactated Ringer's » gelofusin » Haemaccel » hydroxyethyl starch > mannitol. The solubilities of the anaesthetics in all priming¯uids increased logarithmically at lower temperatures (P<0.05). The volume-fraction estimates of the partition coef®cients were within approximately T20% of the measured values for all values of solubility. The corresponding estimates of solubility for CPB blood samples were between ±36% and +24% of the measured values. During normothermic CPB, blood solubility of volatile anaesthetics would be unchanged when using plasma, slightly reduced when using banked blood and markedly reduced when using crystalloids and colloids. During cardiopulmonary bypass (CPB), volatile anaesthetics can be added to the oxygenator to provide anaesthesia, 1 2 regulate systemic vascular resistance 3 4 and reduce hormonal responses to CPB.
During cardiopulmonary bypass (CPB), volatile anaesthetics can be added to the oxygenator to provide anaesthesia, 1 2 regulate systemic vascular resistance 3 4 and reduce hormonal responses to CPB. 5 6 The rate of wash-in and wash-out of volatile anaesthetics via oxygenators depends on their solubility in blood. 7 Two important factors affect the solubility of volatile anaesthetics: hypothermia increases solubility, 7±12 but crystalloid haemodilution decreases it. 11 12 Although the effect of hypothermia on solubilities in saline and plasma has been studied, 12 and although the effects of hypothermia and crystalloid haemodilution on blood solubility of halothane, en¯urane and iso¯urane have been observed in CPB, 13±16 the solubility of volatile anaesthetics in colloid and other priming¯uids has not been investigated. Data for the recently introduced agent, des¯urane, are limited. To provide such information for predicting blood/gas partition coef®cients (l B/G ) during CPB, we studied the following: (i) solubility of des¯urane, iso¯urane and halothane in eight CPB priming¯uids; (ii) effect of temperature on the solubility of these anaesthetics in four CPB priming¯uids; (iii) estimated and measured solubilities of the three anaesthetics in different combinations of the four priminḡ uids at different temperatures; and (iv) predicted and measured l B/G of the three agents during hypothermic CPB.
Solubility of volatile anaesthetics in eight CPB priming¯uids
The solubilities of des¯urane, iso¯urane and halothane in banked blood (Blood Bank, Beijing, China), plasma (Blood Bank, Beijing), normal saline (China Dazhong, Tianjing, China), lactated Ringer's solution (China Dazhong, Tianjing, China), gelofusin (Braun, Switzerland), Haemaccel (Behring, Germany), hydroxyethyl starch (Changshu Pharmaceutical, Jiangshu, China) and mannitol (ZhenDa TianQing, Jiangshu, China) were measured by gas chromatography (see below). We used 10 samples of each solution at 37°C. To compare fresh whole blood with banked blood, the solubility in fresh whole blood (Fuwai Hospital, Beijing, China) and ACD solution (Fuwai Hospital) was measured. Collection of fresh whole blood was approved by the Committee of Scienti®c Research in Fuwai Hospital and informed consent was obtained from each of the 10 male healthy volunteers aged 23 (22±25) yr (mean (range)).
Effect of temperature on solubility of anaesthetics in CPB priming¯uids
The solubility of des¯urane, iso¯urane and halothane in lactated Ringer's solution (a crystalloid solution), gelofusin (a colloid solution), plasma and banked blood was measured at 37, 33, 29, 25, 21 and 17°C. We used six samples of each uid at each temperature.
Solubility of anaesthetics in mixtures of different priming¯uids
Lactated Ringer's solution, gelofusin, plasma and banked blood were mixed in different proportions, as determined by a computer, to give 494 mixtures, each with a volume of approximately 270 ml. We randomly chose 10 of these mixtures which had different proportions of the four constituents ( Table 1 ). The solubilities of des¯urane, iso¯urane and halothane in these 10 mixtures were measured at 37, 33, 29, 25, 21 and 17°C, using six samples from each mixture at each temperature. Estimated l of the mixtures was calculated from the equation: estimated l=S(l x QF x ) where l x is the solubility of the agent in each constituent x and F x is the fractional concentration of each constituent in the total mixture. We called this the volume fraction partition coef®cient.
Solubility of anaesthetics in blood during CPB
After approval from the Committee of Scienti®c Research in Fuwai Hospital, we obtained informed consent from 20 adult patients undergoing valve replacement surgery requiring CPB. Patients were anaesthetized using total intravenous anaesthesia. Lactated Ringer's solution or gelofusin was administered before CPB. The CPB circuit were primed with lactated Ringer's solution and gelofusin. Blood samples were taken 15 min after the beginning of CPB to allow a steady state to be reached after haemodilution by priming¯uid. Urine output, type and volume of infused uids, and CPB priming¯uid were noted. Blood loss was estimated before the blood sample was collected. The solubility of des¯urane, iso¯urane and halothane in each blood sample (measured l B/G of diluted blood in CPB) were measured at 37, 33, 29, 25, 21 and 17°C. The solubilities of the three anaesthetics in each blood sample were estimated using the concept of volume fraction partition coef®cient. The method is given in the Appendix.
Gas chromatography and determination of solubility
Anaesthetic concentration was measured with a GOW-MAC 580 gas chromatograph equipped with a 6 m stainless steel column (0.32 cm internal diameter) packed with Chromosorb-P60/80 mesh maintained at 75°C. We used a 10 ml min ±1 nitrogen carrier¯ow, and a¯ame ionization detector supplied with hydrogen at 35 ml min ±1 and air at 300 ml min ±1 . The output was passed to a TAI-SSC922 integrator and peak areas were calculated. Under these conditions, the peaks of des¯urane, iso¯urane and halothane were completely separated. Primary and secondary (compressed gas tank) standards were used for calibration. Primary standards were made by injecting an aliquot of each anaesthetic into a glass¯ask of known volume with a syringe. Because of the high saturated vapour pressure of des¯urane, we took steps to ensure that no des¯urane was lost. Liquid des¯urane and the syringe were kept at 4°C in a refrigerator. Liquid des¯urane was drawn into the cool syringe at 4°C in the refrigerator and was injected into thē ask or tank immediately. The primary standards (glass ask) were used to calibrate the secondary standards; the secondary standards (tank) were injected at intervals to calibrate the gas chromatograph during each study. All R 2 of the linear regression between concentration of anaesthetics Solubilities of volatile anaesthetics in CPB primes and blood and peak area of gas chromatography output were higher than 0.9995 throughout the study. The regression equation was used to convert peak area to agent concentration. Peak areas were proportional to concentrations over the entire range of the concentrations tested. A gas mixture of des¯urane, iso¯urane and halothane for equilibration in solubility determination was prepared as follows. A stainless steel cylinder (8.1 litres) was evacuated to a pressure of about 0.5 atm less than ambient. Liquid des¯urane, iso¯urane and halothane were aspirated into the cylinder and the cylinder was ®lled with compressed air. We calculated the volume of the three liquid anaesthetics transferred into the cylinder and the compressed air pressure required in the cylinder to ensure that the total pressure of each anaesthetic in the cylinder was <90% of its saturated vapour pressure. The cylinder was rolled for 30 min to mix the contents in the cylinder thoroughly. The anaesthetic concentrations in the cylinder were then calibrated using the primary standard; it contained 1.65% des¯urane, 1.78% iso¯urane and 1.85% halothane.
A 20 ml gas-tight glass syringe, calibrated precisely and capped with a three-way stopcock, was sealed by coating the plunger with a thin layer of silicone grease. The gastightness of these grease-sealed syringes was tested before the study: the concentrations of anaesthetic vapours in the syringes decreased by no more than 2% over 8 h. This also showed that the grease did not absorb anaesthetic. Approximately 7 ml of liquid sample was drawn into a syringe and the above-mentioned anaesthetic gas mixture was added to give 18 ml; the three-way stopcock was then closed. The syringe was shaken vigorously and immersed in a waterbath at the chosen test temperature. Every 15 min for 2 h, the syringe was shaken vigorously for 5±10 s. After the third shaking, the plunger of the syringe was withdrawn to the 20 ml position with the stopcock closed, causing a small negative pressure in the syringe. The stopcock was then opened brie¯y to allow air into the syringe and to restore ambient pressure in the syringe. After this 2 h period (the ®rst equilibration period), the concentration of anaesthetic (C 1 ) in the gas phase of the syringe was analysed by gas chromatography. All the gas and some of the liquid in the syringe were expelled and exactly 4 ml of liquid sample (V L ) was retained in the syringe for the second equilibration. Vapour-free air was drawn in to move the plunger to the 18 ml position. The syringe was shaken vigorously and immersed in the waterbath with the same temperature as in the ®rst equilibration period. The second equilibration had the same sequence of shaking, volume adjustment and timing as in the ®rst equilibration. At the end of the second equilibration period, the concentrations of anaesthetics in gas phase (C 2 ) were analysed by gas chromatography.
The total amount of anaesthetic (ml, in liquid plus gas phase) after the second equilibration is equal to that in the liquid phase which was retained in syringe after the ®rst equilibration. This relationship can be expressed as:
where V G and V L are the gas volume and sample volume retained in the syringe for the second equilibration, respectively; C L1 and C L2 are the anaesthetic concentrations in liquid samples at the end of the ®rst and second equilibration, respectively. l is de®ned as the ratio of anaesthetic concentration (vol%) in liquid phase to that in gas phase (vol%), e.g. C L1 =lQC 1 and C L2 =lQC 2 . Substituting these into equation (1) yields:
This equation can be rearranged to give:
Equation (3) was used to calculate l.
Statistical analysis
Means and standard deviations were obtained for l in priming¯uids and blood. Solubilities in each priming¯uid at 37°C for each anaesthetic were compared with those in fresh whole blood using Student's t-test. The ratio of mean solubility in each priming¯uid and mean solubility in fresh whole blood (R P/B ) was calculated. Repeated-measures analysis of variance was used to determine the difference among the three anaesthetics for each priming¯uid. We related log e l in each¯uid to temperature, and calculated residual standard deviation (RSD) and 95% con®dence limits (CL) of the slope and intercept of the regression lines.
To assess the concept of volume fraction partition coef®-cient and the methods of predicting solubility given in the Appendix, regression and Bland and Altman's`limits of agreement' analysis 17 were performed between estimated l in mixtures of priming¯uids and in CPB blood and the corresponding measured l. P<0.05 was accepted as statistically signi®cant. Table 2 shows the solubility of des¯urane, iso¯urane and halothane measured at 37°C. Their solubilities in fresh whole blood were not signi®cantly different from those in plasma (P>0.05), but were signi®cantly greater than those in the other priming¯uids and in ACD solution (P<0.05).
Results
For all three anaesthetics, the liquid/gas partition coef®cients increased as temperature decreased (Table 3 ; four CPB priming¯uids in step (ii), diluted blood during CPB in step (iv)). To estimate l in CPB blood in step (iv), we used l values from our previous study. 18 The solubilities were in the order: des¯urane < iso¯urane < halothane in all conditions. As temperature decreased, log e l increased linearly (P<0.05). The temperature coef®cient of l (percentage change in l per degree centigrade) was calculated. 19 Details of the ®tted linear equations for the dependence of log e l on temperature are given in Table 4 . The RSDs are in terms of log e l and lie between 0.021 and 0.075 for different media at different temperatures; these correspond to RSDs of between 2.1% and 7.5% of the arithmetic values of l.
As anticipated, log e l of des¯urane, iso¯urane and halothane in the prime mixtures increased linearly as temperature decreased. We found a direct linear relationship between logarithm of estimated l (log e l e ) and measured l (log e l m ) in mixed primes for des¯urane, iso¯urane and halothane (P<0.05, Figure 1A ). Figure 1B shows the`limits of agreement' analysis between estimated and measured log e l. The mean difference between estimated and measured log e l was ±0.010 and the SD was 0.105, which indicated that the estimated l in the mixtures of primes were within +22% and ±20% of the measured values of l.
A direct linear relationship was found between the logarithm of estimated l (log e l e , calculated according to Appendix) and measured l (log e l m ) in CPB blood (P<0.05, Figure 2A ). Figure 2B shows the`limits of agreement' analysis between estimated and measured log e l. The mean difference between estimated and measured log e l was ±0.115 and the SD was 0.164, which indicated that the estimated l in the CPB blood were within +24% and ±36% of the measured values of l.
Discussion
Although volatile anaesthetics are regularly used for open heart surgery, the solubility of anaesthetics in different CPB priming¯uids has not been described before. Partition coef®cients in all primes at 37°C were smallest with des¯urane and greatest with halothane, a similar pattern as in fresh whole blood. This suggests that the differences in pharmacokinetics between the Table 2 Solubility of des¯urane, iso¯urane and halothane in eight priming¯uids, fresh whole blood and ACD solution at 37°C (n=10). Data are shown as mean (SD) [95% CL]. R P/B is the ratio of mean solubility in each priming¯uid to mean solubility in fresh whole blood for a given anaesthetic
Priming¯uid
Des¯urane Iso¯urane Halothane Solubilities of volatile anaesthetics in CPB primes and blood three anaesthetics will not be affected during CPB. However, when a priming¯uid is mixed with blood, the solubility in blood will decrease to an extent which depends on R P/B (Table 2) ; the smaller the ratio, the greater the reduction in l for the mixture. For all the three anaesthetics tested, R P/B of the eight priming¯uids are in the following order: plasma (~1.00) > banked blood > normal saline » lactated Ringer's solution » gelofusine » Haemaccel » hydroxyethyl starch » ACD solution > mannitol (Table 2 ). This order implies that, during normothermic infusion and normothermic CPB, l in diluted blood would be unchanged by using plasma, slightly decreased by using banked blood and greatly decreased by using crystalloid and colloid solutions. As anticipated, reduction in temperature caused an increase in solubility of the anaesthetics in all priminḡ uids, mixtures and CPB blood. This is consistent with the change for fresh whole blood. 7±12 18 Table 3 gives the temperature coef®cients of l. Taking all agents and all solutions tested in this study into account, no correlation was found between temperature coef®cient and its l at 37°C. However, for a given solution (with a minor exception for lactated Ringer's), the magnitudes of the temperature coef®cients were in the same order as the partition coef®cients at 37°C: des¯urane < iso¯urane < halothane.
We assumed that the solubility of an anaesthetic in a mixture of different solutions is equal to the sum of the solubility in each component multiplied by its volume fraction, a concept we call`volume fraction partition coef®cient'. This concept was substantiated in this study. For example, 1 unit of banked blood (250 ml in volume) used in this study consists of 200 ml (80% in volume fraction) whole blood and 50 ml (20% in volume fraction) ACD solution, and solubility of des¯urane in banked blood at 37°C would be (0.52Q80%)+(0.29Q20%). The estimated solubilities of des¯urane, iso¯urane and halothane in banked blood were 0.47, 1.18 and 2.10, respectively, almost identical to the measured solubilities of banked blood (0.45, 1.17 and 2.14, respectively; Table 2 ). We also estimated solubility in 10 mixtures containing different proportions of priming¯uids and found a close relationship between measured and estimated solubility ( Figure 1A ). The limits of agreement (equal to meanT2 SD of the differences, which will include about 95% of the data points) are 0.201 and ±0.221 ( Figure 1B) . We have shown that the solubility of volatile anaesthetics in CPB primes can be predicted and that the concept of volume fraction partition coef®cient is useful for the prediction.
For the agents studied, wash-in and wash-out will be quickest for des¯urane and slowest for halothane at any given temperature, and slower at low temperature for all agents (Table 3) , but quicker on dilution of blood with priming¯uids (other than plasma) ( Table 2) . During CPB, hypothermia will increase anaesthetic blood solubility and haemodilution will reduce it. The effects of these two factors on blood solubility of halothane, en¯urane and iso¯urane have been observed in CPB.
13±16 It is not practical to monitor the solubility of the anaesthetics during CPB. If body temperature and the nature and degree of haemodilution by priming¯uid are monitored, solubility can be estimated to within about ±36% to 24% of the measured value (Figure 2) . Therefore, changes in the rates of wash-in and wash-out of the anaesthetics are likely. Table 4 Regression equations for predicting solubility from temperature (°C) for four priming¯uids, fresh whole blood (from previous study 18 ) and CPB blood. Log e l=slopeQT(°C)+intercept. Our methods have some limitations. We cannot accurately estimate blood loss and circulating blood volume and did not take metabolism of colloid into account. This may have caused the systematically greater value of limits of agreement in predicting l in CPB blood than that in prime mixtures (±36% to +24% in CPB blood compared with about T20% in prime mixtures). However, our method will help anaesthetists judge changes in blood solubility of volatile anaesthetics during CPB, and the effect of this change on their pharmacokinetics. Fig 1 (A) Logarithm of estimated l in prime mixtures (log e l e ) plotted against logarithm of measured l. There were 180 samples, representing the mean l values of three anaesthetics in 10 mixtures of priming¯uids at six temperatures. A direct linear relationship was found between log e l e and log e l m (P<0.05). (B) Differences between log e l m and log e l e in mixtures of priming¯uids plotted against corresponding log e l e . The mean difference between log e l m and log e l e (±1.006Q10
±2
) and meanT2 SD (0.201 to ±0.221) are shown. Fig 2 (A) Logarithm of estimated l in CPB blood (log e l e ) are plotted against logarithm of measured l. There were 360 samples, representing the mean l values of the three anaesthetics in 20 patients at six temperatures. A direct linear relationship was found between log e l e , and log e l m (P<0.05). (B) Differences between log e l m and log e l e of CPB blood plotted against corresponding log e l e . The mean difference between log e l m and log e l e (±0.115) and meanT2 SD (0.214 to ±0.444) are shown.
Appendix: estimating the solubility of volatile anaesthetics in CPB blood (1) Estimate following circulating volumes (ml): (i) fresh whole blood volume (V fwb ), i.e. patient's body weight (kg) multiplied by 70 (ml kg ±1 ); (ii) net added crystalloid volume (V cry ), i.e. (infused crystalloid plus primed crystalloid minus urine output)/3; (iii) added colloid volume (V col ), i.e. infused colloid plus primed colloid; (iv) added banked blood volume (V bb ), i.e. infused banked blood plus primed banked blood; (v) added plasma volume (V p ), i.e. infused plasma plus primed plasma; and (vi) total circulating blood volume (V total ) = V fwb +V cry +V col +V bb +V p .
(2) Calculate solubilities for fresh whole blood (l fwb ), crystalloid (l cry ), colloid (l col ), banked blood (l bb ) and plasma (l p ) at the temperature at which l is estimated by using the equations in Table 4 .
(3) Estimated l of CPB blood=((V fwb Ql wb )+(V cry Q l cry )+(V col Ql col )+(V bb Ql bb )+(V p Ql p ))/V total
